Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast with teleconference, Q3'24

By Inderes10/24/2024, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:00 - 13:38

Head. Thank you. Operator, welcome to the presentation of the Bactiguard Q3 2024 report. I will go through the presentation together with my colleague Patrick Bach, our CFO, and open up for questions towards the end. Thank you all for dialing in today. Let's go straight into the overarching theme of the report. We are very pleased to announce profitability on an EBITDA level, both for the third quarter and year to date. This is a demonstration that our licensed, focused strategy and business model, which we embarked on late last year, is working and effective. As you know, we also had some disappointing news in early October after the end of the quarter when Zimmer Biomet terminated the agreement covering multiple orthopedic product segments. The broad commercial potential in these segments was a key driver of our 2020 financial targets. Considering this, and to further seize the opportunity for reflection after last year's transformation work, we have decided to initiate a review of our financial targets. The outcome will be communicated in Q1 2025. Importantly, our partnership with Zimmer Biomet within the trauma segment remains in effect, and I will return to the Zimmer partnership later in the presentation. I wanted to give some brief overall comments on the financial development of the third quarter, and as usual, Patrick will review these in more detail later in the presentation. Our total revenues for Q3 amounted to 73.9 million SEK, an increase of almost 50% compared to the same period last year. We report a positive EBITDA of 9.9 million SEK for the third quarter, which means that we have become profitable on an EBITDA level, not just for the quarter, but also year to date. The profitability was delivered from a combination of increased revenues, where solid growth within the BD partnership was the main driver, as well as a disciplined approach to costs. Another highlight of the quarter was the strong performance of the Wound Management portfolio. Overall, while we are humble about the challenges ahead and acknowledge that we still have much to do, we remain committed to delivering EBITDA profitability for 2020. For a quick recap of what Bactiguard does. Our unique infection prevention technology is an ultra-thin coating of the noble metals gold, silver, and palladium. We license the technology to global medtech companies and develop a different coating process for each medical device. The total quantities of the noble metals on any given device, however, are minimal. But when in contact with fluids, the galvanic effect creates something akin to an electric fence, resulting in the inhibition of microbe adherence to the surface of the devices. In the pictures in the lower right of the slide taken with an electron microscope, you can see the difference in bacterial colonization between an uncoated surface on the left and a Bactiguard-coated surface on the right. The Bactiguard side shows significantly fewer bacteria colonizing, which reduces biofilm formation over time and leads to lowered rates of infection over the years. A wealth of data has been amassed, all pointing to the effectiveness of our technology. More than 100,000 patients have been part of over 40 clinical trials covering case reports to randomized controlled trials, and the results have been published in renowned peer-reviewed publications. Our studies cover various patient cohorts, continents, and regions, and different therapeutic areas. In short, we know our technology works. The need for infection prevention is increasing due to the challenges in delivering effective healthcare globally. Sepsis, which I mentioned in my CEO statement, is merely one example of the importance of prevention. 50 million people contract sepsis when an infection goes astray, and more than 11 million die each year. In addition, the demand for more effective and safe healthcare solutions is driven by economic and demographic developments, increased political unrest, conflicts, wars, and natural disasters. There are many unmet medical needs that arise from these pressing global societal challenges, including sepsis, healthcare-associated infections, and antimicrobial resistance. The medical need also brings commercial opportunities for Bactiguard within our various strategic therapeutic areas. In fact, they drive home our mission to work with leading MedTech companies to enable differentiated medical devices to be brought to the market. We see an increased interest in our infection prevention technology, and I will comment further on that shortly. Wound Management clearly represents a significant market size and growth opportunity, considering the positive Q3 momentum in our Wound Management portfolio. One year has passed since we embarked on the journey towards a sharpened, license-focused strategy around our coating technology, and we have undergone a fundamental shift, going from production and sales to becoming a knowledge specialist and licensed partnership organization. Reaching EBITDA profitability for 2024 already in the third quarter serves as excellent evidence that our strategy and business model are effective, and that the transformation is well underway and making progress. Our overarching focus areas remain the same: licensed partnerships, strengthening the knowledge and specialist organization further, and growing our Wound Management portfolio profitably. I would like to take a deeper dive into the license-related green boxes. Our key priority is working in partnership with leading global MedTech players, and this includes two core parts. Firstly, advancing current partnerships where the positive development of the relationship with BD is a great example, which I will come back to in a few minutes. And secondly, by developing new licensing partnerships. We do this by delivering our competencies into our partnerships to develop processes and IP, demonstrate patient benefit, and enhance our partners' product differentiation. This relationship is a virtuous cycle. The more we understand and educate the market about our technology and its ability to mitigate infection risk, the more interest we see in our technology platform, the stronger our partnerships become, enabling us to continue developing our competencies and so on. In this context, I would like to revisit our business model, which we introduced in connection with the Q3 report last year. The green section is clearly the most important from a revenue generation perspective. Our revenues are generated in three categories: application development, exclusivity fees, and license revenues. Our work to deliver partnerships begins earlier, however, in the beige part of the figure. As I noted before, we are seeing increased interest in our infection prevention technology from global MedTech players, and we are currently exploring the application of our technology across various strategic therapeutic areas. Our R&D team is currently engaged in early-stage testing in collaboration with potential partners across various therapeutic areas. We are testing the performance of our technology on various medical devices, materials, and surfaces. This early stage testing and even full application development projects are best executed in a confidential manner, and we are committed to safeguarding competitive advantages for our partners, particularly at this stage of the partnership journey. Additionally, some application development projects will materialize and some will not. This is a natural part of our business. In accordance with our business model, we are announcing partners once the early stage projects convert into exclusivity and licensed partnerships. We believe this provides a more relevant perspective on when meaningful revenues from the partnerships will commence. Now, let's turn to more on our licensed partnerships. Looking at the quarter in isolation, the solid growth in revenues from BD was the main driver of our positive EBITDA. We have had three stable quarters and now see growth. Reviewing the collaboration both over the last nine months and through the third quarter, we are extremely pleased with how the partnership has developed. We now have a truly global approach and are working even more closely together on the expansion of Bactiguard-coated Foley catheters into both existing and new markets. Our collaboration has transitioned into a strategic partner cooperation, and Bactiguard now engages with BD across the entire value chain from technology through to market. Here you see a recent photo of the collaboration, with the Bactiguard BD project leader to the left and a BD representative to the right. At the Urology Week event organised by the Swedish Urological Association in Norrköping, Sweden. Importantly, the evolution of the relationship with BD demonstrates how our license-focused strategy is proving effective. It is a global approach in close partnership, and it is growing. BD's success is Bactiguard's success. Returning to Zimmer Biomet, the termination of the agreement covering multiple orthopedic product segments in early October was clearly a disappointment. While Zimmer Biomet are strong believers in the importance of infection prevention and our technology, they informed us that they were not prepared to commit to a more complex and lengthier US FDA pathway than originally anticipated. The agreement for these segments was signed back in 2022. We are now in dialogue with Zimmer Biomet to detail the near-term responsibilities and analyze the longer-term impact of the termination. While the termination was a disappointment, Bactiguard now fully owns the rights and is free to seek additional partnerships within orthopedic segments outside of trauma, where our agreement with Zimmer Biomet does remain in effect. Within the trauma setting, infection rates are significantly higher than, for example, in elective reconstructive procedures, and consequently, the need for infection prevention is more pressing. In the partnership, we are working together on regulatory processes in Europe and the US, and we continue to support the commercialization activities for the Z-n Bactiguard trauma nail, especially in Europe. A highlight in Q3 was the way Zimmer Biomet presented our technology at the European Bone and Joint Infection Society's conference in Barcelona. A trauma implant placed in an interactive glass cylinder illustrated the mode of action. Your finger represented. The microbes touching the cylinder, and the light effect demonstrated the prevention of attachment to the device. Zimmer Biomet also arranged a cool event on infection prevention measures for metal implants, highlighting our technology. The event in Barcelona is yet another example of the continued commercial collaboration between Bactiguard and Zimmer Biomet within trauma. Here in the final photo are our Zimmer Biomet Alliance manager and our CMO, along with colleagues from Zimmer Biomet. Separate from the technology licensing focus, we continue to grow in the Wound Management portfolio. The product portfolio had a strong third quarter and continued its trajectory of profitable growth. These pictures are from this past weekend, where we participated in the Global Wound Conference in Selangor, Malaysia, organized by the International Wound Infection Institute. Additionally, a few days ago, the results of a randomized study with Hydrocyn aqua were published in the British Journal of Surgery. The study showed that using Hydrocyn aqua solution in peritoneal and wound lavage reduced overall surgical site infections by 58% and superficial surgical site infections by 72%. These significant results further reinforce the efficacy of Hydrocyn aqua in infection prevention. In addition to Hydrocyn aqua, our wound management portfolio consists of a wide range of surgical sutures, including specialty sutures for cardiovascular and ocular operations. And with that, I will hand over to Patrick Bach, our CFO, to go through our financials in more detail.

Patrick Bach
13:40 - 20:59

Thank you. Christine. I am very happy to present our financial results for Q3 and the nine-month period year-to-date. In short, we deliver positive EBITDA and demonstrate that our license-focused strategy and business model is effective. At the same time, we will review our 2028 financial targets due to the CMO's termination of the orthopedics agreement. As Christine mentioned, the potential in these segments was a key driver of our financial targets, and the outcome of our review will be communicated in Q1 2025. Now, turning to our actual revenue split for Q3. In the quarter, our total license revenue amounted to $47.5 million, an increase of almost $27 million. Adjusted for currency effects of minus 4 million, our license revenues increased by almost 150%. Revenues from BD amounted to $33.3 million, an increase of more than 24 million. This increase mainly pertained to the stock adjustment made by BD during Q2 and Q3 last year. Revenues from Zimmer Biomet amounted to 10.7 million SEK, a decrease just under a million. And these revenues consist of license revenues from royalties, including minimum royalties and application development revenues. Notably, most of the revenues are related to the Continuing Trauma agreement. Revenues from the Wound Management portfolio amounted to $17.9 million, an increase of $0.4 million, corresponding to 2% with and without currency effects. Revenues from our BIP portfolio amounted to just under 2 million SEK, a decrease of more than 5 million. The BIP portfolio will continue to decrease as our inventory depletes and we cease production. Other revenues amounted to $6.6 million, and within this, we saw total currency effects of 4.6 million SEK. So in Q3, our total revenue amounted to $73.9 million. As Christine mentioned, an increase of 24 million and almost 50%, while for the nine month period from January to September, our total revenues amounted to 193.6 million, an increase of almost 32 million. Adjusted for positive currency effects of 7.6 million, our total revenues increased by 15%. Now, looking at our net sales. So overall, net sales grew, driven by solid growth in our license revenues in Q3. Net sales amounted to $67 million, an increase of almost $22 million, corresponding to 48% growth for the first nine months of the year. Net sales amounted to 179 million, an increase of more than 33 million, corresponding to 23% growth. As mentioned, we see growth in our license revenues as well as in the Wound Management portfolio. While we see the continued phase-out of the BIP portfolio. Now turning to EBITDA development. As Christine mentioned, we are very pleased to announce profitability at the EBITDA level both for the third quarter and for the nine-month period. Year to date, EBITDA for the third quarter amounted to 9.9 million, an increase of just over 19 million, and the EBITDA margin was 13%. The improved Q3 result mainly pertained to the increase in total license revenues while keeping costs under control. EBITDA for the period January to September amounted to 9.6 million, an increase of more than 81 million, and the improved result year to date obviously mainly pertained to the SEK 42 million provision made in the second quarter of last year in connection with the increase in total license revenues we see. Year to date, there has been a decrease in total operating expenses. Now turning to operating expenses and cash flow. Costs for raw materials and consumables amounted to -6.9 million, a decrease of almost 4 million. Other external costs amounted to -27.8 million, an increase of just over 6 million. Personnel costs for the quarter amounted to -24.9 million. Other operating expenses amounted to -4 million, a small increase of 0.9 million, and in total for Q3, our OpEx amounted to -56.9 million, an increase of 7.1 million. Year to date for the nine-month period, we see our total opex amounting to 153.5 million and a decrease of 31.6 million, or just about 17%. So all in all, we are on track to deliver cost savings exceeding 25 million on a yearly basis, as previously communicated following the strategic transformation last year. Now turning to cash flow. Cash flow from our operating activities in Q3 amounted to a positive 8.3 million. Cash flow from investing activities was -2.9 million, and cash flow from our financing activities was -3.9 million. In total for the quarter, the total cash flow was a positive 1.6 million. Year to date, total cash flow amounts to -20.5 million. And all in all, cash and cash equivalents at the end of September and the end of the period was 106.4 million SEK. Now, with that, I'm happy to hand it over to you, Christine.

Christine Lind
21:00 - 23:18

Thank you, Patrick, for that review of our solid financial position. Before wrapping up, I'd like to revisit our priorities going forward, where maintaining focus remains a key component. We continue to work relentlessly on advancing our current partnerships, where BD serves as an excellent blueprint for successful global collaboration, growth, and mutual benefit, and as evidence of our sharpened strategy. Simultaneously, we are increasing interactions and early stage testing of our infection prevention technology with potential partners on various medical devices in our strategic therapeutic areas, and once converted to application development projects, we will announce the licensing partnerships to the market. We also continue to build and strengthen our knowledge and specialist areas, including our core competencies within R&D, medical, and regulatory affairs. This will enable us to continue to deliver future partnerships in our therapeutic areas, where there is a strong unmet medical need for infection prevention. As always, we also remain focused on driving profitable growth in our Wound Management portfolio. We have come far in our transformation. The positive financial development, reflected both in our revenue growth and in our positive EBITDA, serves as clear evidence that our strategy and business model are effective, and we will continue to work to deliver profitability and sustainable growth. We have many of the building blocks in place, including an experienced and dedicated team who will deliver on our new strategy and drive towards our vision of becoming the global standard of care to prevent infection. Medical device-related infections. We remain committed to profitability for 2024. While we are humble about the challenges ahead, we acknowledge that we still have a lot to deliver. I am optimistic about our path forward and thrilled to be able to deliver a profitable quarter and year to date. With that, we would like to hand over to the operator to open up for questions.

Operator
23:23 - 23:43

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Matthias Waddesdon from SEB. Please go ahead.

Matthias Waddesdon
23:46 - 24:30

Hello. Thanks for the presentation. First of all, I guess it would be helpful to hear what makes you confident that Zimmer is in it for the long term with regard to the trauma implants? I guess the effort to reach a broad commercial launch has taken time there as well. And also, to that question, what can you share about the timing for FDA approval of Bactiguard-coated trauma implants? Should we interpret the press release on Zimmer as indicating a slow development here, and that a delay in the regulatory timeline for trauma implants is reasonable to consider? That's the first one.

Christine Lind
24:33 - 25:45

Hi, Mathias. Thank you for those questions. Excellent. In terms of our collaboration with Zimmer in trauma, we definitely continue to work together within the trauma area. As I noted, both in terms of the regulatory pathway and in collaborating on commercial development moving forward in the markets. We do see continued commitment here. We also know from Zimmer's own comments to the market how much they believe in the technology and how important infection prevention is to them. It is one of their banners on a corporate basis as well. In terms of the timelines for FDA approval, one thing to note is that the infection rates in trauma are higher than in other areas. This leads to an increased ability to demonstrate effect in this particular category. Um, we do not, however, have an updated timeline in terms of FDA approval in these categories, and so I am not able to communicate any new information there.

Matthias Waddesdon
25:49 - 26:17

And that's clear. And then, just looking at the 24 million through license revenues from royalties, exclusivity revenues, and application development revenues, as you write in the report regarding Zimmer, could you give a more detailed split here and also confirm how much of that is related to the expanded agreements and trauma, respectively? That's the next one.

Patrick Bach
26:20 - 26:33

Thank you. Thank you, Matthias. As I understand your question, it is regarding the total revenues booked for Zimmer and how that relates to the different agreements. Is that correct?

Matthias Waddesdon
26:35 - 26:36

That's correct.

Patrick Bach
26:38 - 28:11

Very well. In total, for the period of the first nine months, we have recorded similar revenues within license revenues, exclusivity revenues, and application development partnership revenues. And as we have communicated before, the accounting principles and how we report the revenues here relate to the activity and to the stage of the partnership. We can, however, report revenues for each agreement in the different categories. And as we have stated before, the majority of the revenues that we recorded under the orthopedics agreement were recorded as exclusivity revenues or milestone revenues, and we do not have an actual split of all the revenues that we have received from Zimmer in the report. But I think if you delve into the three different sections of the license revenues, you will see that we have recorded revenues for Zimmer in the license category, the exclusivity category, and the application development revenue category this year.

Matthias Waddesdon
28:15 - 28:44

So thanks for that. It sounds like it is a minor part then from the expanded agreement. And then, how would you describe the development with BD in the quarter? Are the volumes we see above the normal levels, making it reasonable to project lower quarters ahead? Or is this the new normal? Let's say, according to your understanding, that's the next one.

Patrick Bach
28:45 - 29:51

Thank you very much, Matthias. And as we have communicated, we are pleased to see the growth in our total license revenues, which is driven by the partnership with BD. That's fully correct. And I think, as we have consistently communicated, it is very important for us to see the stability and growth in the BD relationship. We have, before this quarter, reported what we felt were three stable quarters of BD revenues. I think it's fair to say that this quarter we see solid growth in BD revenues, which is obviously a testament to the global strengthening of the relationship we have with BD. Whether it's a new normal for us going forward, I think we have to prove that in the coming quarters. But we remain confident in the continuation and the growth of the relationship with BD.

Matthias Waddesdon
29:54 - 29:57

Thank you. I think I will have to jump back in the queue.

Patrick Bach
29:59 - 30:00

Thank you. Thank you, Matthias.

Operator
30:02 - 30:07

The next question comes from Ludvig Svensson from Carnegie Investment Bank. Please go ahead.

Ludvig Svensson
30:09 - 30:21

Yeah. Hello. And thank you for taking my questions. Regarding the Wound Management portfolio and its steady growth, what are your next steps for further expanding this area? Would you say?

Christine Lind
30:23 - 31:16

Uh, strategically. I'll be happy to answer that question, and then I'll ask Patrick to comment on it financially as well. As you noted, we do see solid growth in the Wound Management area. These remain in our core markets, and we would expect that we continue to focus on a steady, incremental type of growth in this category where we will attempt to grow profitably. The expansion is certainly about us continuing to highlight the benefits of the product in the market, as demonstrated in one of the publications, for example, on the benefits of the hydrazine product line itself. And we do see hydrazine as a key growth driver for this portfolio. Patrick, if you would like to comment further.

Patrick Bach
31:16 - 32:04

Yeah, just to second that, I think what we have communicated previously, which is still the case, is that we are focused on delivering profitable growth for the Wound Management segment. And so, the run rate we see for this quarter shows positive growth. Although the comparable year for Q3 last year was also a strong quarter. We continue to focus on driving growth in the Wound Management business. And as Christine said, we want this to come from the strategically important products such as hydrazine, and we are focused and careful in the expansion of new markets. So we continue to grow profitably.

Ludvig Svensson
32:08 - 32:12

Great. Thank you. That was everything I had for the moment.

Unknown 1
32:14 - 32:14

Thank you.

Patrick Bach
32:14 - 32:15

Thank you.

Operator
32:17 - 32:21

The next question comes from Matthias Waddesdon from Seb. Please go ahead.

Unknown 2
32:24 - 32:24

Yes.

Matthias Waddesdon
32:24 - 32:56

Hi. Two follow-ups from me. I think that when we examine operating expenses and observe good cost control, which has been consistent this year, I appreciate that you might not comment on the specifics of development for 2025 just yet. However, it seems there is a lot happening within the organization in terms of projects. So could you share some comments on how you internally plan resources, etc.? For the future, we aim to offer a structurally better understanding. That's the next one for me.

Patrick Bach
32:58 - 33:46

Yeah. Thank you, Matthias. You're absolutely correct. It has indeed been. And it will continue to be a focus for us this year to demonstrate that we have the OpEx under control, as well as maintaining a focus on the cost of goods. Um, while we do that, we want to grow profitably. So we also at the same time want to make sure we are making the right investments into the business. As you will see from our cash flow statements, we are still making relevant investments into the business and we will continue to do so. The important balance for us is to invest in the business while we continue to grow profitably, and that is what we remain committed to in 2025 as well.

Matthias Waddesdon
33:49 - 34:08

So it is reasonable to expect a higher operating expense in 2025 versus, let's say, 2024, given that sales seem to be growing. And yes, you have a lot of projects going on. How can you give us some insights into that?

Patrick Bach
34:09 - 34:50

Yeah, I think the flavor that I can certainly give is that we will continue to make the right investments into the business as we see them in front of us. Um, but we will still be committed to delivering profitable growth and a continuous increase in our profitability. I cannot comment specifically on what the OpEx will look like a year from now. But we remain committed in our journey and our path towards profitability while still investing in the business.

Unknown 1
34:52 - 34:52

Matthias, I.

Christine Lind
34:52 - 35:24

I will additionally highlight and answer the question that while we do continue to invest in the competencies of specialists and the knowledge organization, we do this in pace with developing new potential strategic partnerships. So the aim, of course, is always to invest in a way that we expect will deliver future revenues as well. So, this is the way that we are approaching the investments in our people and competencies.

Matthias Waddesdon
35:26 - 35:47

Good. I think that's pretty clear. Thanks for that. And then the last question from me today would be if you could update us also on the, let's say, status with Well Lead. Also, could you give us an update on the activity with them and when they placed their last order with us?

Patrick Bach
35:50 - 36:18

Thank you. Thank you. Thank you, Matthias. We have our existing collaboration with Well Lead for the China market. We remain confident about the opportunities in China long term. Yes, we have recorded revenues this year from our partnership with Well Lead. And we have also done that in this quarter.

Matthias Waddesdon
36:23 - 36:26

Okay. Thank you for the presentation and the answers.

Patrick Bach
36:27 - 36:27

Thank you. Mathias.

Operator
36:32 - 36:53

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Christine Lind
36:54 - 37:11

Thank you again, everyone, for dialing in to today's quarterly report. As we mentioned, we are always pleased to have everyone with us on each of our calls, and we continue to commit to delivering in the quarters ahead. Looking forward to seeing you next time. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…